Vimarsana
Biggest News Aggregation in the World

Page 45 - Stem Cell Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stem Cell Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stem Cell Therapy Today - Breaking & Trending Today

33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells - Vimarsana News

33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells

Engraftment of Vertex Pharmaceutical's VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year.

Stem cell-based regenerative therapy to treat heart failure - Vimarsana News

Stem cell-based regenerative therapy to treat heart failure

A new study saw pluripotent (immature) stem cells cultivated in the laboratory to grow into heart muscle precursor cells, which can develop into various types of heart cells.

Bayer: Phase I trial results from Parkinson's cell therapy positive - Vimarsana News

Bayer: Phase I trial results from Parkinson's cell therapy positive

Bayer subsidiary BlueRock has become the first company to report initial success treating Parkinson's disease in humans using an experimental stem cell therapy, the drugmaker said on Wednesday. The hunt for Parkinson's treatments has seen many setbacks over decades. Bayer said that one year into a Phase I trial with 12 volunteers, BlueRock's therapy was shown to be well-tolerated and that transplanted cells grew as intended in patients' brains.

Source: yahoo.com
Stem Cell Therapy - Basics - Vimarsana News

Stem Cell Therapy - Basics

Stem cell therapy or regenerative medicine uses undifferentiated cells for the treatment of conditions like leukemia.

Gilteritinib Maintenance Reduces Relapse in MRD+ AML - Vimarsana News

Gilteritinib Maintenance Reduces Relapse in MRD+ AML

Patients with acute myeloid leukemia and who have minimal residual disease following hematopoietic cell transplantation have a reduced risk of relapse with gilteritinib maintenance therapy.